Radiopharmaceuticals labelled with 18F are the most studied compounds in nuclear medicine, especially for positron emission tomography (PET). Recent studies are engaged in developing new compounds for PET, which should be more specific in certain processes than the widespread 2-deoxy-2-[18F]fluoro-D-glucose ([18F] FDG). Novel radiopharmaceutical compounds trace cell metabolism, such as protein synthesis, amino acid transport, or nucleoside synthesis. Several promising fluorinated compounds are introduced.
18F-Labelled compounds as active substances of radiopharmaceuticals are used for imaging in positron emission tomography (PET) in nuclear medicine. The radiosynthesis of PET radiopharmaceuticals is based on nucleophilic substitution with F- in a precursor. The synthesis is demonstrated on 3?-deoxy-3?-[18F]fluorothymidine.
